Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Long-term efficacy and downstream mechanism of anti-annexinA2 monoclonal antibody (anti-ANX A2 mAb) in a pre-clinical model of aggressive human breast cancer.

Sharma MC, Tuszynski GP, Blackman MR, Sharma M.

Cancer Lett. 2016 Apr 1;373(1):27-35. doi: 10.1016/j.canlet.2016.01.013. Epub 2016 Jan 18.

PMID:
26797420
2.

Angiocidin induces differentiation of acute myeloid leukemia cells.

Tuszynski GP, Rothman VL.

Exp Mol Pathol. 2013 Dec;95(3):249-54. doi: 10.1016/j.yexmp.2013.08.001. Epub 2013 Sep 13.

PMID:
24036285
3.

G-protein coupled receptor-associated sorting protein 1 (GASP-1), a ubiquitous tumor marker.

Zheng X, Chang F, Zhang X, Rothman VL, Tuszynski GP.

Exp Mol Pathol. 2012 Aug;93(1):111-5. doi: 10.1016/j.yexmp.2012.03.013. Epub 2012 Mar 24.

PMID:
22483848
4.

G-protein coupled receptor-associated sorting protein 1 (GASP-1), a potential biomarker in breast cancer.

Tuszynski GP, Rothman VL, Zheng X, Gutu M, Zhang X, Chang F.

Exp Mol Pathol. 2011 Oct;91(2):608-13. doi: 10.1016/j.yexmp.2011.06.015. Epub 2011 Jul 23.

PMID:
21791203
5.

Angiocidin inhibits breast cancer proliferation through activation of epidermal growth factor receptor and nuclear factor kappa (NF-ĸB).

Godek J, Sargiannidou I, Patel S, Hurd L, Rothman VL, Tuszynski GP.

Exp Mol Pathol. 2011 Jun;90(3):244-51. doi: 10.1016/j.yexmp.2011.01.002. Epub 2011 Jan 15.

6.

Thrombospondin 1, fibronectin, and vitronectin are differentially dependent upon RAS, ERK1/2, and p38 for induction of vascular smooth muscle cell chemotaxis.

Willis AI, Sadowitz B, Fuse S, Maier KG, Lee TS, Wang XJ, Tuszynski GP, Sumpio BE, Gahtan V.

Vasc Endovascular Surg. 2011 Jan;45(1):55-62. doi: 10.1177/1538574410387677.

PMID:
21193465
7.
8.

The interaction of angiocidin with tissue transglutaminase.

L'Heureux DZ, Rothman VL, Tuszynski GP.

Exp Mol Pathol. 2010 Feb;88(1):15-25. doi: 10.1016/j.yexmp.2009.11.001. Epub 2009 Nov 18.

9.

Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: exploring the functional significance in tumor cell invasion.

John AS, Hu X, Rothman VL, Tuszynski GP.

Exp Mol Pathol. 2009 Dec;87(3):184-8. doi: 10.1016/j.yexmp.2009.09.002. Epub 2009 Sep 9.

10.

The immunomodulatory role of angiocidin, a novel angiogenesis inhibitor.

Gaurnier-Hausser A, Tuszynski GP.

Curr Pharm Des. 2009;15(17):1937-48.

PMID:
19519434
11.

Pharmaceutical and cellular strategies of recent advances in immunotherapy.

Tuszynski G, Sharma M.

Curr Pharm Des. 2009;15(17):1936. No abstract available.

PMID:
19519433
12.

Effect of VP12 and viperistatin on inhibition of collagen-receptor-dependent melanoma metastasis.

Staniszewska I, Walsh EM, Rothman VL, Gaathon A, Tuszynski GP, Calvete JJ, Lazarovici P, Marcinkiewicz C.

Cancer Biol Ther. 2009 Aug;8(15):1507-16. Epub 2009 Aug 13.

PMID:
19502781
13.

Regulatory effect of nerve growth factor in alpha9beta1 integrin-dependent progression of glioblastoma.

Brown MC, Staniszewska I, Lazarovici P, Tuszynski GP, Del Valle L, Marcinkiewicz C.

Neuro Oncol. 2008 Dec;10(6):968-80. doi: 10.1215/15228517-2008-047.

14.

Angiostatic activity of obtustatin as alpha1beta1 integrin inhibitor in experimental melanoma growth.

Brown MC, Staniszewska I, Del Valle L, Tuszynski GP, Marcinkiewicz C.

Int J Cancer. 2008 Nov 1;123(9):2195-203. doi: 10.1002/ijc.23777.

15.

The novel angiogenic inhibitor, angiocidin, induces differentiation of monocytes to macrophages.

Gaurnier-Hausser A, Rothman VL, Dimitrov S, Tuszynski GP.

Cancer Res. 2008 Jul 15;68(14):5905-14. doi: 10.1158/0008-5472.CAN-07-6179.

16.

Integrin alpha9 beta1 is a receptor for nerve growth factor and other neurotrophins.

Staniszewska I, Sariyer IK, Lecht S, Brown MC, Walsh EM, Tuszynski GP, Safak M, Lazarovici P, Marcinkiewicz C.

J Cell Sci. 2008 Feb 15;121(Pt 4):504-13. doi: 10.1242/jcs.000232. Epub 2008 Jan 29.

17.

Angiocidin promotes pro-inflammatory cytokine production and antigen presentation in multiple sclerosis.

Kremlev SG, Gaurnier-Hausser AL, Del Valle L, Perez-Liz G, Dimitrov S, Tuszynski G.

J Neuroimmunol. 2008 Feb;194(1-2):132-42. doi: 10.1016/j.jneuroim.2007.11.003. Epub 2008 Jan 22.

PMID:
18207252
18.

Angiocidin inhibitory peptides decrease tumor burden in a murine colon cancer model.

Liebig C, Agarwal N, Ayala GE, Verstovsek G, Tuszynski GP, Albo D.

J Surg Res. 2007 Oct;142(2):320-6. Epub 2007 Aug 23.

PMID:
17719063
19.

Interaction of alpha9beta1 integrin with thrombospondin-1 promotes angiogenesis.

Staniszewska I, Zaveri S, Del Valle L, Oliva I, Rothman VL, Croul SE, Roberts DD, Mosher DF, Tuszynski GP, Marcinkiewicz C.

Circ Res. 2007 May 11;100(9):1308-16. Epub 2007 Apr 5.

PMID:
17413041
20.

Clinical significance of serum angiocidin levels in hepatocellular carcinoma.

Sabherwal Y, Rothman VL, Poon RT, Tuszynski GP.

Cancer Lett. 2007 Jun 18;251(1):28-35. Epub 2006 Dec 22.

21.

Reduction of angiocidin expression in human umbilical vein endothelial cells via siRNA silencing inhibits angiogenesis.

Yang X, Rothman VL, L'Heureux DZ, Tuszynski G.

Exp Mol Pathol. 2006 Oct;81(2):108-14. Epub 2006 Aug 10.

PMID:
16904104
22.

Integrin alpha2beta1 mediates the anti-angiogenic and anti-tumor activities of angiocidin, a novel tumor-associated protein.

Sabherwal Y, Rothman VL, Dimitrov S, L'Heureux DZ, Marcinkiewicz C, Sharma M, Tuszynski GP.

Exp Cell Res. 2006 Aug 1;312(13):2443-53. Epub 2006 Apr 30.

PMID:
16762342
23.

Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression.

Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP, Sharma MC.

Exp Mol Pathol. 2006 Oct;81(2):146-56. Epub 2006 Apr 27.

PMID:
16643892
25.

Endothelial apoptotic activity of angiocidin is dependent on its polyubiquitin binding activity.

Dimitrov S, Sabherwal Y, Raymond DD, L'Heureux DZ, Lu Q, Tuszynski GP.

Br J Cancer. 2005 Sep 19;93(6):662-9.

26.

Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma.

Poon RT, Chung KK, Cheung ST, Lau CP, Tong SW, Leung KL, Yu WC, Tuszynski GP, Fan ST.

Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4150-7.

28.

Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin-1.

Zhou J, Rothman VL, Sargiannidou I, Dimitrov S, Qiu C, Smith E, Sheffield J, Sharma M, Tuszynski GP.

J Cell Biochem. 2004 May 1;92(1):125-46.

PMID:
15095410
29.

[The influence of adrenalectomy on the treatment of arterial hypertension in patients with benign adrenal medullary and cortical tumors].

Ziaja JM, Cierpka LD, Król RJ, Gasińska TE, Tuszyński GJ, Cholewa KW, Kajor MW.

Wiad Lek. 2003;56(11-12):545-51. Polish.

PMID:
15058162
30.

Mechanisms of thrombospondin-1-mediated metastasis and angiogenesis.

Sargiannidou I, Qiu C, Tuszynski GP.

Semin Thromb Hemost. 2004 Feb;30(1):127-36. Review.

PMID:
15034804
31.

Antiangiogenic therapy.

Albo D, Wang TN, Tuszynski GP.

Curr Pharm Des. 2004;10(1):27-37. Review.

PMID:
14754403
32.
33.

Obtustatin: a potent selective inhibitor of alpha1beta1 integrin in vitro and angiogenesis in vivo.

Marcinkiewicz C, Weinreb PH, Calvete JJ, Kisiel DG, Mousa SA, Tuszynski GP, Lobb RR.

Cancer Res. 2003 May 1;63(9):2020-3.

34.

Angiostatin binds to tyrosine kinase substrate annexin II through the lysine-binding domain in endothelial cells.

Tuszynski GP, Sharma MR, Rothman VL, Sharma MC.

Microvasc Res. 2002 Nov;64(3):448-62.

PMID:
12453439
35.

Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer.

Albo D, Shinohara T, Tuszynski GP.

J Surg Res. 2002 Nov;108(1):51-60.

PMID:
12443715
36.

Thrombospondin-1 promotes proliferative healing through stabilization of PDGF.

Krishnaswami S, Ly QP, Rothman VL, Tuszynski GP.

J Surg Res. 2002 Sep;107(1):124-30.

PMID:
12384074
37.
38.

Thrombospondin-1 may modulate keloid formation through up-regulation of the matrix-associated plasminogen/plasmin system.

Centeno RF, Albo D, Rothman VL, Granick MS, Tuszynski GP.

Plast Reconstr Surg. 2002 Jul;110(1):363-5. No abstract available.

PMID:
12087300
39.

Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production.

Qian X, Rothman VL, Nicosia RF, Tuszynski GP.

Pathol Oncol Res. 2001;7(4):251-9.

40.

The role of thrombospondin-1 in tumor progression.

Sargiannidou I, Zhou J, Tuszynski GP.

Exp Biol Med (Maywood). 2001 Sep;226(8):726-33. Review.

PMID:
11520937
41.

The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis.

John A, Tuszynski G.

Pathol Oncol Res. 2001;7(1):14-23. Review.

42.

The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.

Wakiyama T, Shinohara T, Shirakusa T, John AS, Tuszynski GP.

Histol Histopathol. 2001 Apr;16(2):345-51. doi: 10.14670/HH-16.345.

PMID:
11332689
43.
44.

Inhibition of phosphatidylinositol 3-kinase and protein kinase C attenuates extracellular matrix protein-induced vascular smooth muscle cell chemotaxis.

Willis AI, Fuse S, Wang XJ, Chen E, Tuszynski GP, Sumpio BE, Gahtan V.

J Vasc Surg. 2000 Jun;31(6):1160-7.

45.

The role of adhesive proteins in the hematogenous spread of cancer.

Zhou J, Sargiannidou I, Tuszynski GP.

In Vivo. 2000 Jan-Feb;14(1):199-208. Review.

PMID:
10757078
46.

Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer.

Albo D, Berger DH, Vogel J, Tuszynski GP.

J Gastrointest Surg. 1999 Jul-Aug;3(4):411-7.

PMID:
10482694
47.

Thrombospondin-1 regulation of smooth muscle cell chemotaxis is extracellular signal-regulated protein kinases 1/2 dependent.

Gahtan V, Wang XJ, Willis AI, Tuszynski GP, Sumpio BE.

Surgery. 1999 Aug;126(2):203-7.

PMID:
10455885
48.

Thrombospondin-1 induces activation of focal adhesion kinase in vascular smooth muscle cells.

Gahtan V, Wang XJ, Ikeda M, Willis AI, Tuszynski GP, Sumpio BE.

J Vasc Surg. 1999 Jun;29(6):1031-6.

49.

Thrombospondin 1 and its specific cysteine-serine-valine-threonine-cysteine-clycine receptor in fetal wounds.

Roth JJ, Sung JJ, Granick MS, Solomon MP, Longaker MT, Rothman VL, Nicosia RF, Tuszynski GP.

Ann Plast Surg. 1999 May;42(5):553-63.

PMID:
10340867
50.

Retinoic acid alters the mechanism of attachment of malignant astrocytoma and neuroblastoma cells to thrombospondin-1.

Pijuan-Thompson V, Grammer JR, Stewart J, Silverstein RL, Pearce SF, Tuszynski GP, Murphy-Ullrich JE, Gladson CL.

Exp Cell Res. 1999 May 25;249(1):86-101.

PMID:
10328956

Supplemental Content

Loading ...
Support Center